Semaglutide plus SGLT2 inhibitors in China

A post hoc analysis of the Chinese SCHOLAR real-world cohort describes outcomes among adults with type 2 diabetes who received once-weekly subcutaneous semaglutide and had at least one sodium-glucose cotransporter-2 inhibitor, or SGLT2 inhibitor, prescription within six months of starting semaglutide. It found lower average HbA1c at six months in the combined-treatment subset, but the single-arm design cannot show that the combination caused the change^[1].

What the analysis examined

SCHOLAR was a real-world study of once-weekly semaglutide use in adults with type 2 diabetes in China. For this post hoc analysis, investigators selected participants prescribed semaglutide plus at least one SGLT2 inhibitor within six months of semaglutide initiation. They divided participants by continuous versus non-continuous semaglutide use and by whether baseline HbA1c was at least 7%. HbA1c is a laboratory measure that reflects average blood glucose over roughly the prior two to three months^[1].

The paper reports that 11,361 participants, or 42.3% of the SCHOLAR cohort, received the combined semaglutide-SGLT2 inhibitor treatment. The listed endpoints were change in HbA1c from baseline to month six, the share reaching HbA1c below 7% at month six, changes in blood-lipid measures, and the safety profile. The publication record identifies the work as a post hoc, single-arm analysis, not a randomized comparison of combination therapy with another treatment strategy^[1].

The six-month findings

In the overall combined-treatment group, mean HbA1c changed by minus 0.64 percentage points at month six, with a reported 95% confidence interval from minus 0.71 to minus 0.56. The largest reported mean change was minus 1.20 percentage points in the continuous-semaglutide subgroup whose baseline HbA1c was at least 7%. Those figures describe changes within observed groups. They do not establish how the same participants would have changed without semaglutide, without an SGLT2 inhibitor, or with a different treatment plan^[1].

The proportion of the overall combined-treatment group with HbA1c below 7% rose from 37.8% at baseline to 55.1% at month six. The authors also reported statistically significant reductions in mean total cholesterol, low-density lipoprotein cholesterol, and triglycerides, alongside a statistically significant increase in high-density lipoprotein cholesterol. The abstract does not provide the size of each lipid change, so it does not support a precise estimate of the clinical importance of those lipid findings^[1].

What the safety result says

Gastrointestinal adverse events were the most frequent events reported in the abstract. The authors concluded that the combination group's safety profile was similar to that of the overall SCHOLAR population. This is a descriptive safety finding from the analyzed cohort, rather than proof that the combination has the same safety profile in every population or in a head-to-head trial. The source record also lists Novo Nordisk China employees and shareholders among the authors, and identifies Novo Nordisk as the study sponsor^[1].

Why the design matters

A post hoc analysis asks a new question using data collected in an existing study or dataset. It can be useful for describing patterns in routine care, including how frequently medicines are used together. Its limits matter here: participants were not randomly assigned to receive a combined regimen, and the source abstract does not describe a control group for estimating the separate contribution of each medicine. Differences in baseline health, prescribing choices, persistence with therapy, and other treatments may influence observed outcomes^[1].

The study therefore should not be read as a dosing guide or as evidence that people should add one medicine to another. Treatment decisions for type 2 diabetes depend on medical history, current medicines, kidney function, glucose targets, tolerability, and local product authorization. Readers looking for a general overview can review our semaglutide resource and our explainer on how peptide regulation works.

What we do not yet know

From the accessible PubMed record, this analysis does not answer whether the combination outperforms semaglutide alone, an SGLT2 inhibitor alone, or another diabetes regimen. It also does not establish a causal effect on HbA1c or lipids, provide a detailed numerical breakdown of adverse events, or show whether the findings apply outside the SCHOLAR setting in China. The record links the report to ClinicalTrials.gov identifier NCT06351748, but this article should be interpreted according to the single-arm post hoc design described by its authors^[1].

Bottom line

This report documents that combined semaglutide and SGLT2 inhibitor prescribing was common in the analyzed SCHOLAR subset and that HbA1c and several lipid measures changed over six months. Context, not a verdict. That distinction matters. The association is useful context for clinicians and researchers examining real-world treatment patterns. It is not evidence that a particular combination is appropriate for an individual, and it does not replace a randomized comparison designed to test benefits and harms^[1].

Medical disclaimer

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.